295 related articles for article (PubMed ID: 32757451)
1. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
[TBL] [Abstract][Full Text] [Related]
2. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
4. Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma.
Deng T; Gong YZ; Wang XK; Liao XW; Huang KT; Zhu GZ; Chen HN; Guo FZ; Mo LG; Li LQ
Med Sci Monit; 2019 May; 25():3716-3727. PubMed ID: 31104065
[TBL] [Abstract][Full Text] [Related]
5. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
6. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
7. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
8. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
10. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
11. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
12. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
18. CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma.
Shi H; Song Y; Song Z; Huang C
PLoS One; 2021; 16(1):e0245524. PubMed ID: 33465115
[TBL] [Abstract][Full Text] [Related]
19. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
20. Prognostic power of a lipid metabolism gene panel for diffuse gliomas.
Wu F; Zhao Z; Chai RC; Liu YQ; Li GZ; Jiang HY; Jiang T
J Cell Mol Med; 2019 Nov; 23(11):7741-7748. PubMed ID: 31475440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
